OTC Markets EXMKT - Delayed Quote USD

Marizyme, Inc. (MRZM)

0.0003
0.0000
(0.00%)
At close: April 23 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
183.4170
645.8100
233.4850
210.2790
197.1360
Cost of Revenue
57.8800
188.1080
54.3190
80.3540
58.2920
Gross Profit
125.5370
457.7020
179.1660
129.9250
138.8440
Operating Expense
12,490.0850
20,299.8430
13,152.9620
8,951.3080
5,938.4470
Operating Income
-12,364.5480
-19,842.1410
-12,973.7960
-8,821.3830
-5,799.6030
Net Non Operating Interest Income Expense
-26,452.0300
-20,142.8070
-2,789.2550
-126.0240
-45.4500
Other Income Expense
23,862.7960
-29,554.3880
-22,402.8190
-2,050.5220
--
Pretax Income
-14,953.7820
-69,539.3360
-38,165.8700
-10,997.9290
-5,845.0530
Net Income Common Stockholders
-14,953.7820
-69,539.3360
-38,165.8700
-10,997.9290
-5,845.0530
Diluted NI Available to Com Stockholders
-14,953.7820
-69,539.3360
-38,165.8700
-10,997.9290
-5,845.0530
Basic EPS
-0.04
-1.53
-0.94
-0.31
-0.22
Diluted EPS
-0.04
-1.53
-0.94
-0.31
-0.22
Basic Average Shares
111,864.7750
45,473.1900
40,727.0920
36,041.6130
26,373.9820
Diluted Average Shares
111,864.7750
45,473.1900
40,727.0920
36,041.6130
26,373.9820
Total Operating Income as Reported
-26,608.9230
-34,086.5160
-37,323.7960
-8,821.3830
-5,799.6030
Total Expenses
12,547.9650
20,487.9510
13,207.2810
9,031.6620
5,996.7390
Net Income from Continuing & Discontinued Operation
-14,953.7820
-69,539.3360
-38,165.8700
-10,997.9290
-5,845.0530
Normalized Income
-38,616.5780
-39,984.9480
-15,760.0510
-8,947.4070
-5,845.0530
Interest Expense
25,916.1170
13,254.3320
2,789.2550
126.0240
45.4500
Net Interest Income
-26,452.0300
-20,142.8070
-2,789.2550
-126.0240
-45.4500
EBIT
10,962.3350
-56,285.0040
-35,376.6150
-10,871.9050
-5,799.6030
EBITDA
11,528.4490
-55,443.7870
-34,535.1710
-10,828.0340
-5,208.1440
Reconciled Cost of Revenue
40.8900
188.1080
54.3190
80.3540
58.2910
Reconciled Depreciation
566.1140
841.2170
841.4440
43.8710
591.4590
Net Income from Continuing Operation Net Minority Interest
-14,953.7820
-69,539.3360
-38,165.8700
-10,997.9290
-5,845.0530
Total Unusual Items Excluding Goodwill
23,662.7960
-29,554.3880
-22,405.8190
-2,050.5220
--
Total Unusual Items
23,662.7960
-29,554.3880
-22,405.8190
-2,050.5220
--
Normalized EBITDA
-12,134.3470
-25,889.3990
-12,129.3520
-8,777.5120
-5,208.1440
12/31/2020 - 9/5/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

KLTO Klotho Neurosciences, Inc.
0.1590
+4.47%
 
LIXT Lixte Biotechnology Holdings, Inc.
1.2560
-4.12%
 
NTHI NeOnc Technologies Holdings, Inc. Common Stock
5.99
+1.87%
 
SILO Silo Pharma, Inc.
1.1400
-0.87%
 
ABVC ABVC BioPharma, Inc.
0.9110
+4.00%
 
OSRH OSR Holdings, Inc.
1.3800
+0.73%
 
TRAW Traws Pharma, Inc.
1.5300
+4.08%
 
TCRT Alaunos Therapeutics, Inc.
2.6800
+8.94%
 
OGEN Oragenics, Inc.
0.1941
+0.05%
 
MTVA MetaVia Inc.
0.8500
+4.55%